Kyra Becker1, Ruth Kohen2, Richard Lee3, Patricia Tanzi3, Dannielle Zierath3, Kevin Cain4, Pamela Mitchell5, Jonathan Weinstein3. 1. Department of Neurology, University of Washington School of Medicine, Seattle, Washington. Electronic address: kjb@uw.edu. 2. Department of Psychiatry, University of Washington School of Medicine, Seattle, Washington. 3. Department of Neurology, University of Washington School of Medicine, Seattle, Washington. 4. Department of Biostatistics, University of Washington School of Medicine, Seattle, Washington. 5. Biobehavioral Nursing and Health Systems, University of Washington School of Nursing, Seattle, Washington.
Abstract
BACKGROUND: Poststroke fatigue (PSF) is common, but the biological basis of this fatigue is unknown. We explored the possibility that PSF is related to systemic inflammation by investigating polymorphisms in 2 genes that affect the immune response. METHODS: In a substudy of a larger trial that evaluated the role of the immune response on stroke outcome, fatigue was assessed at 30, 90, 180, and 365 days after ischemic stroke using the Fatigue Assessment Scale. Subjects were genotyped for 3 single nucleotide polymorphisms, one in the interleukin-1 receptor antagonist gene (IL1RN; rs4251961, a T/C substitution) and two in the in toll-like receptor-4 (TLR4) gene (1063 A/G [Asp299Gly] rs4986790 and 1363 C/T [Thr399Ile] rs4986791). RESULTS: Of the 39 participants, 22 (56%) endorsed fatigue during the study. The degree of fatigue was remarkably constant over time and independent of stroke outcome. The C allele of the rs4251961 single nucleotide polymorphism (SNP) in IL1RN was associated with self-reported fatigue (P = .03), whereas the cosegregating polymorphisms in TLR4 were associated with lower levels of fatigue (P= .04). CONCLUSIONS: SNPs in 2 genes with opposing effects on inflammatory immune responses were significantly, but differentially, associated with PSF. These findings suggest a direct link between immune signaling dysregulation and PSF.
BACKGROUND:Poststroke fatigue (PSF) is common, but the biological basis of this fatigue is unknown. We explored the possibility that PSF is related to systemic inflammation by investigating polymorphisms in 2 genes that affect the immune response. METHODS: In a substudy of a larger trial that evaluated the role of the immune response on stroke outcome, fatigue was assessed at 30, 90, 180, and 365 days after ischemic stroke using the Fatigue Assessment Scale. Subjects were genotyped for 3 single nucleotide polymorphisms, one in the interleukin-1 receptor antagonist gene (IL1RN; rs4251961, a T/C substitution) and two in the in toll-like receptor-4 (TLR4) gene (1063 A/G [Asp299Gly] rs4986790 and 1363 C/T [Thr399Ile] rs4986791). RESULTS: Of the 39 participants, 22 (56%) endorsed fatigue during the study. The degree of fatigue was remarkably constant over time and independent of stroke outcome. The C allele of the rs4251961 single nucleotide polymorphism (SNP) in IL1RN was associated with self-reported fatigue (P = .03), whereas the cosegregating polymorphisms in TLR4 were associated with lower levels of fatigue (P= .04). CONCLUSIONS: SNPs in 2 genes with opposing effects on inflammatory immune responses were significantly, but differentially, associated with PSF. These findings suggest a direct link between immune signaling dysregulation and PSF.
Authors: N C Arbour; E Lorenz; B C Schutte; J Zabner; J N Kline; M Jones; K Frees; J L Watt; D A Schwartz Journal: Nat Genet Date: 2000-06 Impact factor: 38.330
Authors: Alexander P Reiner; Mark M Wurfel; Leslie A Lange; Christopher S Carlson; Alex S Nord; Cara L Carty; Mark J Rieder; Cindy Desmarais; Nancy S Jenny; Carlos Iribarren; Jeremy D Walston; O Dale Williams; Deborah A Nickerson; Gail P Jarvik Journal: Arterioscler Thromb Vasc Biol Date: 2008-05-01 Impact factor: 8.311
Authors: Bart Ferwerda; Matthew B B McCall; Santos Alonso; Evangelos J Giamarellos-Bourboulis; Maria Mouktaroudi; Neskuts Izagirre; Din Syafruddin; Gibson Kibiki; Tudor Cristea; Anneke Hijmans; Lutz Hamann; Shoshana Israel; Gehad ElGhazali; Marita Troye-Blomberg; Oliver Kumpf; Boubacar Maiga; Amagana Dolo; Ogobara Doumbo; Cornelus C Hermsen; Anton F H Stalenhoef; Reinout van Crevel; Han G Brunner; Djin-Ye Oh; Ralf R Schumann; Concepcion de la Rúa; Robert Sauerwein; Bart-Jan Kullberg; André J A M van der Ven; Jos W M van der Meer; Mihai G Netea Journal: Proc Natl Acad Sci U S A Date: 2007-10-09 Impact factor: 11.205
Authors: S Rafiq; K Stevens; A J Hurst; A Murray; W Henley; M N Weedon; S Bandinelli; A M Corsi; J M Guralnik; L Ferruci; D Melzer; T M Frayling Journal: Genes Immun Date: 2007-04-19 Impact factor: 2.676
Authors: J R Sims; L Rezai Gharai; P W Schaefer; M Vangel; E S Rosenthal; M H Lev; L H Schwamm Journal: Neurology Date: 2009-06-16 Impact factor: 9.910
Authors: N Jennifer Klinedinst; Rosemary Schuh; Steven J Kittner; William T Regenold; Glenn Kehs; Christine Hoch; Alisha Hackney; Gary Fiskum Journal: J Bioenerg Biomembr Date: 2019-01-07 Impact factor: 2.945
Authors: Megan E Roerink; Marieke E van der Schaaf; Charles A Dinarello; Hans Knoop; Jos W M van der Meer Journal: J Neuroinflammation Date: 2017-01-21 Impact factor: 8.322
Authors: Solveig K Hammonds; Maria B Lauvsnes; Ingvild Dalen; Mona K Beyer; Kathinka D Kurz; Ole J Greve; Katrine B Norheim; Roald Omdal Journal: Rheumatol Adv Pract Date: 2017-10-17
Authors: Milanka M Visser; Peter Goodin; Mark W Parsons; Thomas Lillicrap; Neil J Spratt; Christopher R Levi; Andrew Bivard Journal: Sci Rep Date: 2019-07-04 Impact factor: 4.379